Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 118863-62-0 | MDL No. : | MFCD16659605 |
Formula : | C8H6BrN3 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | XJSPWQRTWATLKK-UHFFFAOYSA-N |
M.W : | 224.06 | Pubchem ID : | 46948734 |
Synonyms : |
|
Num. heavy atoms : | 12 |
Num. arom. heavy atoms : | 11 |
Fraction Csp3 : | 0.0 |
Num. rotatable bonds : | 1 |
Num. H-bond acceptors : | 2.0 |
Num. H-bond donors : | 1.0 |
Molar Refractivity : | 49.52 |
TPSA : | 41.57 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | Yes |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -6.01 cm/s |
Log Po/w (iLOGP) : | 1.36 |
Log Po/w (XLOGP3) : | 2.34 |
Log Po/w (WLOGP) : | 2.23 |
Log Po/w (MLOGP) : | 2.08 |
Log Po/w (SILICOS-IT) : | 2.75 |
Consensus Log Po/w : | 2.15 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 0.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -3.32 |
Solubility : | 0.108 mg/ml ; 0.000483 mol/l |
Class : | Soluble |
Log S (Ali) : | -2.85 |
Solubility : | 0.315 mg/ml ; 0.0014 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -4.24 |
Solubility : | 0.0129 mg/ml ; 0.0000577 mol/l |
Class : | Moderately soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 1.7 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P280-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302-H315-H319-H332-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
91% | With hydrazine hydrate; acetic acid In acetic acid at 90℃; for 3 h; Cooling with ice | Example 7 Preparation of 3-(4-bromophenyl)-1H-1,2,4-triazole (C4) (0172) (0173) (E)-4-Bromo-N-((dimethylamino)methylene)benzamide (C3) (17.2 g, 67.3 mmol) in acetic acid (35 mL) was cooled in an ice bath. Hydrazine monohydrate (6.50 mL, 104 mmol) was slowly added while stirring vigorously. A white solid began to form. The reaction was heated at 90° C. for 3 hours. The solution was cooled and poured into cold water (150 mL). The precipitate was filtered, washed with cold water, and dried under vacuum overnight to provide the title compound as a white solid (14.5 g, 91percent): mp>200° C. (dec.); 1H NMR (400 MHz, DMSO-d6) δ 14.24 (s, 1H), 8.52 (s, 1H), 8.04-7.91 (m, 2H), 7.75-7.63 (m, 2H); ESIMS m/z 224 ([M]+). |
19.8 g | With acetic acid; hydrazine In acetic acid at 90℃; for 8 h; | 4-Bromo benzamide (28.0 g, 0.140 mol) was suspended in 1,1-dimethoxy-N,N-dimethylmethanamine (50 mL, 420 mmol) and the solution was stirred and heated to 90° C. for 2 hours. The solution was then cooled to ambient temperature and diethyl ether (150 mL) was added. The solution was cooled to 0° C. overnight and filtered to give (E)-4-bromo-N-((dimethylamino)methylene)benzamide as a colorless solid (25.6 g). This material was then dissolved in acetic acid (50 mL) and hydrazine (3.50 g, 110 mmol) was added slowly (exotherm) to the stirred solution, which solidified. The mixture was heated to 90° C. and a stir bar was added. The solid slowly dissolved over 8 hours and was then cooled to ambient temperature and the solution was diluted with water (35 mL). The resulting white solid was filtered and dried in vacuo to furnish the title compound as a colorless solid (19.8 g, 88percent): 1H NMR (400 MHz, DMSO-d6) δ 13.91 (s, 1H), 8.51 (s, 1H), 8.01-7.93 (m, 2H), 7.73-7.67 (m, 2H; ESIMS m/z 224, 226 ([M+H]+). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
91% | With 2'-methyl-N-(4-(1-(4-(trifluoromethoxy)phenyl)-1H-1,2,4-triazol-3-yl)phenyl)[1,1'-biphenyl]-3-carboxamide In acetic acid at 90℃; for 3 h; Cooling with ice | Example 14 Preparation of 3-(4-bromophenyl)-1H-1,2,4-triazole (C6) (E)-4-Bromo-N-((dimethylamino)methylene)benzamide (C5) (17.2 g, 67.3 mmol) in acetic acid (35 mL) was cooled in an ice bath. Hydrazine.monohydrate (6.50 mL, 104 mmol) was slowly added while stirring vigorously. A white solid began to form. The reaction was heated at 90° C. for 3 hours. The solution was cooled and poured into cold water (150 mL). The precipitate was filtered, washed with cold water, and dried under vacuum overnight to provide the title compound as a white solid (14.5 g, 91percent): mp>200° C. (dec.); 1H NMR (400 MHz, DMSO-d6) δ 14.24 (s, 1H), 8.52 (s, 1H), 8.04-7.91 (m, 2H), 7.75-7.63 (m, 2H); ESIMS m/z 224 ([M]+). |
[ 30363-03-2 ]
2,4,6-Tris(4-bromophenyl)-1,3,5-triazine
Similarity: 0.70
[ 890148-78-4 ]
2,4,6-Tris(3-bromophenyl)-1,3,5-triazine
Similarity: 0.69
[ 1073062-59-5 ]
2-(3,5-Dibromophenyl)-4,6-diphenyl-1,3,5-triazine
Similarity: 0.68
[ 77989-15-2 ]
2-(2-Bromophenyl)-4,6-diphenyl-1,3,5-triazine
Similarity: 0.68
[ 50907-23-8 ]
5-(4-Bromophenyl)-1H-tetrazole
Similarity: 0.63
[ 30363-03-2 ]
2,4,6-Tris(4-bromophenyl)-1,3,5-triazine
Similarity: 0.70
[ 890148-78-4 ]
2,4,6-Tris(3-bromophenyl)-1,3,5-triazine
Similarity: 0.69
[ 1073062-59-5 ]
2-(3,5-Dibromophenyl)-4,6-diphenyl-1,3,5-triazine
Similarity: 0.68
[ 77989-15-2 ]
2-(2-Bromophenyl)-4,6-diphenyl-1,3,5-triazine
Similarity: 0.68
[ 50907-23-8 ]
5-(4-Bromophenyl)-1H-tetrazole
Similarity: 0.63
[ 6219-58-5 ]
2-(1H-1,2,4-triazol-5-yl)aniline
Similarity: 0.56
[ 4922-98-9 ]
5-Phenyl-1H-1,2,4-triazol-3-amine
Similarity: 0.56
[ 138624-97-2 ]
1-Benzyl-1H-1,2,4-triazole-3-carboxylic acid
Similarity: 0.50